Incorporating adherence into health economic modelling of osteoporosis (Osteoporosis International DOI: 10.1007/s00198-008-0644-9);Incorporating adherence into health economic modelling of osteoporosis

Osteoporosis International

Volumn 20, Issue 1, 2009, Pages 23-34

  Strom O ^a,b   Borgstrom F ^a,b   Kanis, J A ^c   Jonsson B ^d  

^a I3 Innovus ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Compliance; Cost effectiveness; Fracture; Model; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; RALOXIFENE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CASE CONTROL STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SUBSTITUTION; FRACTURE; HEALTH ECONOMICS; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MODEL; MORTALITY; OSTEOPOROSIS; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; VERTEBRA FRACTURE; WRIST FRACTURE;

EID: 57049102313     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0693-0     Document Type: Erratum

References (53)

1. L Osterberg T Blaschke 2005 Adherence to medication N Engl J Med 353 487 497
2. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460
3. E Seeman J Compston J Adachi ML Brandi 2007 Non-compliance: the Achilles' heel of anti-fracture efficacy Osteoporos Int 18 711 719
4. KF Huybrechts KJ Ishak JJ Caro 2006 Assessment of compliance with osteoporosis treatment and its consequences in a managed care population Bone 38 922 928
5. DT Gold S Silverman 2006 Review of adherence to medications for the treatment of osteoporosis Curr Osteoporos Rep 4 21 27
6. B Jonsson C Christiansen O Johnell J Hedbrandt 1996 Cost-effectiveness of fracture prevention in established osteoporosis Scand J Rheumatol Suppl 103 30 38
7. JA Kanis F Borgstrom O Johnell A Odén 2005 Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study Osteoporos Int 16 15 25
8. M Stevenson M Lloyd Jones E De Nigris N Brewer 2005 A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis Health Technol Assess 9 1 160
9. F Borgstrom B Jonsson O Strom JA Kanis 2006 An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials Osteoporos Int 17 1781 1793
10. O Strom F Borgstrom SS Sen S Boonen 2007 Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial Osteoporos Int 18 1047 1061
11. PM Fayers DJ Hand 1997 Generalisation from phase III clinical trials: survival, quality of life, and health economics Lancet 350 1025 1027
12. G Simon E Wagner M Vonkorff 1995 Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs J Clin Epidemiol 48 363 373
13. DH Solomon J Avorn JN Katz JS Finkelstein 2005 Compliance with osteoporosis medications Arch Intern Med 165 2414 2419
14. D Weycker D Macarios J Edelsberg G Oster 2006 Compliance with drug therapy for postmenopausal osteoporosis Osteoporos Int 17 1645 1652
15. Jones ML, Wilkinson A (2006) Adverse effects and persistence with therapy in patients taking oral alendronate, etidronate or risedronate: systematic reviews (NICE). University of Sheffield, School of Health and Related Research ( http://www.nice.org.uk/guidance/index.jsp?action=download&o=36718 )
16. D Weycker D Macarios J Edelsberg G Oster 2007 Compliance with osteoporosis drug therapy and risk of fracture Osteoporos Int 18 271 277
17. ES Siris HK Genant AJ Laster P Chen 2007 Enhanced prediction of fracture risk combining vertebral fracture status and BMD Osteoporos Int 18 761 770
18. E McCloskey D De Takats J Orgee S Aropinn 2005 Characteristics associated with non-persistence during daily therapy. Experience from the placebo wing of a community based clinical trial J Bone Miner Res 20 Suppl 1 S282
19. JA Kanis F Borgstrom C De Laet H Johansson 2005 Assessment of fracture risk Osteoporos Int 16 581 589
20. A Ekedahl N Mansson 2004 Unclaimed prescriptions after automated prescription transmittals to pharmacies Pharm World Sci 26 26 31
21. DM Black AV Schwartz KE Ensrud JA Cauley 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 2927 2938
22. F Borgstrom O Johnell JA Kanis A Odén 2004 Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study Pharmacoeconomics 22 1153 1165
23. O Johnell B Jonsson L Jonsson D Black 2003 Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures Pharmacoeconomics 21 305 314
24. S Ortolani S Vai 2006 Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages Bone 38 19 22
25. DJ Wallace 2005 Rapid prevention of vertebral fractures associated with osteoporosis Orthopedics 28 291 298
26. Statistics Sweden. Swedens Statistical Databases. http://wwwscbse/eng/ databaser/ssdasp
27. JA Kanis O Johnell A Odén I Sembo 2000 Long-term risk of osteoporotic fracture in Malmo Osteoporos Int 11 669 674
28. JA Kanis O Johnell A Odén B Jonsson 2000 Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden Osteoporos Int 11 120 127
29. CE De Laet BA van Hout H Burger A Hofman 1997 Bone density and risk of hip fracture in men and women: cross sectional analysis Br Med J 315 221 225
30. Borgstrom F, Zethraeus N, Johnell O, Lidgren L et al (2005) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 1-14
31. O Johnell B Gullberg JA Kanis 1997 The hospital burden of vertebral fracture in Europe: a study of national register sources Osteoporos Int 7 138 144
32. N Zethraeus O Strom F Borgstrom 2006 What is the risk of institutionalization after hip fracture? Osteoporosis Int 17 Suppl 2 S60
33. Stockholms stads budgetavräkning 2003. http://www.stockholm.se/ files/71600-71699/file_71645.pdf. Accessed 20 December 2004
34. Ström O, Borgstrom F, Zethraeus N, Johnell O et al (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop (accepted)
35. A Oleksik P Lips A Dawson ME Minshall 2000 Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures J Bone Miner Res 15 1384 1392
36. A Odén A Dawson W Dere O Johnell 1998 Lifetime risk of hip fractures is underestimated Osteoporos Int 8 599 603
37. O Johnell JA Kanis A Odén I Sernbo 2004 Mortality after osteoporotic fractures Osteoporos Int 15 38 42
38. MJ Parker JK Anand 1991 What is the true mortality of hip fractures? Public Health 105 443 446
39. JA Kanis A Odén O Johnell C De Laet 2003 The components of excess mortality after hip fracture Bone 32 468 473
40. JA Cauley DE Thompson KC Ensrud JC Scott 2000 Risk of mortality following clinical fractures Osteoporos Int 11 556 561
41. N Zethraeus F Borgstrom O Strom JA Kanis 2007 Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model Osteoporos Int 18 9 23
42. IOF Cost-effectiveness reference model ( http://www.iofbonehealth.org/ health-professionals/health-economics/iof-cost-effectiveness-reference-model. html
43. CH van den Boogaard NS Breekveldt-Postma SE Borggreve WG Goettsch 2006 Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study Curr Med Res Opin 22 1757 1764
44. Gujarati DN (1995) Basic econometrics. McGraw Hill, Singapore
45. JA Kanis M Stevenson EV McCloskey S Davis 2007 Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis Health Technol Assess 11 1 256
46. Stevenson M, Davies S (2006) DSU economic evaluation of pooled alendronate and risedronate compared with strontium ranelate, raloxifene, etidronate and teriparatide. http://guidance.nice.org.uk/page.aspx?o=370643
47. DM Black PD Delmas R Eastell IR Reid 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 1809 1822
48. Y Liel H Castel DY Bonneh 2003 Impact of subsidizing effective anti-osteoporosis drugs on compliance with management guidelines in patients following low-impact fractures Osteoporos Int 14 490 495
49. LA Lillard J Rogowski R Kington 1999 Insurance coverage for prescription drugs: effects on use and expenditures in the Medicare population Med Care 37 926 936
50. N Zethraeus L Stromberg B Jonsson O Svensson 1997 The cost of a hip fracture. Estimates for 1,709 patients in Sweden Acta Orthop Scand 68 13 17
51. JA Kanis O Johnell A Odén I Sembo 2000 Long-term risk of osteoporotic fracture in Malmö Osteoporos Int 11 669 674
52. LJ Melton III SE Gabriel CS Crowson AN Tosteson 2003 Cost-equivalence of different osteoporotic fractures Osteoporos Int 14 383 388
53. JS McCombs P Thiebaud C McLaughlin-Miley J Shi 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271 287